Premium
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Author(s) -
Zhu J.,
Song Y.,
Smith S.D.,
O'Connor O.A.,
Luo W.,
Shazer R.L.,
Zhang L.,
Han I.,
Jivani M.A.,
Liu Y.,
Nowakowski G.S.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.37_2629
Subject(s) - medicine , oncology , placebo , chop , diffuse large b cell lymphoma , hazard ratio , randomized controlled trial , phases of clinical research , pharmacology , clinical trial , lymphoma , pathology , confidence interval , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom